Concurrence
Excessive Pricing in Pharmaceuticals
|
Affordable access to many drugs is made difficult by high prices. At the same time, serious questions are being asked about the degree of innovation and value offered by increasingly costly treatments. A number of competition enforcement actions against excessive pricing have recently taken place in the pharmaceutical sector, despite competition authorities usually being reluctant to intervene directly against high prices. In common with other instances of application of competition law in the pharmaceutical sector, these cases require a deep understanding of market dynamics and sectoral regulation, and of the various regulatory responses that may be deployed to address high prices. In November 2018, the OECD held a discussion on excessive prices at the intersection between competition law and regulated sectors such as pharma. All related materials for the discussion are available on this page.
View the full list of OECD best practice roundtables on competition policy
INVITED SPEAKERS John DAVIES Bio Margherita COLANGELO Bio Margaret KYLE Bio
KEY PAPERS
OECD background note • Note de référence de l'OCDE Executive Summary with key findings • Synthèse des points clés de la discussion Detailed Summary of the discussion • Compte rendu detaillé de la discussion
|
OECD Competition Youtube channel WATCH ALSO 2019 Session on excessive prices in pharmaceutical markets, OECD Competition Open Day
|
||
|
|
28 November 2018 
Paris 
PRESENTATIONS
|
RELATED DOCUMENTS AND LINKS Excessive prices in pharmaceutical markets, 2019 OECD Competition Open Day Competition issues in the distribution of pharmaceuticals, 2014 Competition and Generic Pharmaceuticals, 2014 Excessive Prices, 2011 Generic Pharmaceuticals, 2009 Monopsony and Buyer Power, 2008 Competition and Regulation Issues in the Pharmaceutical Industry, 2000 |
RELATED TOPICS Abuse of dominance and monopolisation Liberalisation and competition intervention in regulated sectors |
Documents connexes